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Intermediate Care Clinics for Diabetes (ICCD):
study protocol for a randomized controlled trial
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Ala Szczepura1*, Andrew Wilson2 and on behalf of the ICCD Study GroupAbstract
Background: World-wide healthcare systems are faced with an epidemic of type 2 diabetes. In the United
Kingdom, clinical care is primarily provided by general practitioners (GPs) rather than hospital specialists.
Intermediate care clinics for diabetes (ICCD) potentially provide a model for supporting GPs in their care of people
with poorly controlled type 2 diabetes and in their management of cardiovascular risk factors. This study aims to (1)
compare patients with type 2 diabetes registered with practices that have access to an ICCD service with those that
have access only to usual hospital care; (2) assess the cost-effectiveness of the intervention; and (3) explore the
views and experiences of patients, health professionals and other stakeholders.
Methods/Design: This two-arm cluster randomized controlled trial (with integral economic evaluation and
qualitative study) is set in general practices in three UK Primary Care Trusts. Practices are randomized to one of two
groups with patients referred to either an ICCD (intervention) or to hospital care (control).
Intervention group: GP practices in the intervention arm have the opportunity to refer patients to an ICCD - a
multidisciplinary team led by a specialist nurse and a diabetologist. Patients are reviewed and managed in the ICCD
for a short period with a goal of improving diabetes and cardiovascular risk factor control and are then referred
back to practice.
or
Control group: Standard GP care, with referral to secondary care as required, but no access to ICCD.
Participants are adults aged 18 years or older who have type 2 diabetes that is difficult for their GPs to control. The
primary outcome is the proportion of participants reaching three risk factor targets: HbA1c (≤7.0%); blood pressure
(<140/80); and cholesterol (<4 mmol/l), at the end of the 18-month intervention period. The main secondary
outcomes are the proportion of participants reaching individual risk factor targets and the overall 10-year risks for
coronary heart disease(CHD) and stroke assessed by the United Kingdom Prospective Diabetes Study (UKPDS) risk
engine. Other secondary outcomes include body mass index and waist circumference, use of medication, reported
smoking, emotional adjustment, patient satisfaction and views on continuity, costs and health related quality of life.
We aimed to randomize 50 practices and recruit 2,555 patients.
Discussion: Forty-nine practices have been randomized, 1,997 patients have been recruited to the trial, and 20
patients have been recruited to the qualitative study. Results will be available late 2012.* Correspondence: Ala.szczepura@warwick.ac.uk
1Warwick Medical School, University of Warwick, Coventry CV4 7AL, UK
Full list of author information is available at the end of the article
© 2012 Armstrong et al.; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the
Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use,
distribution, and reproduction in any medium, provided the original work is properly cited.
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Configuring services so that all people with type 2 dia-
betes mellitus (T2DM) can benefit from good quality,
target-driven and patient-focused care is a major chal-
lenge to healthcare systems such as the UK National
Health Service (NHS), especially given the increased and
increasing prevalence. In recent years there has been a
shift in place of care from hospital to general practice [1].
Although the new contract for general practices set tar-
gets for the control of diabetes, concerns were voiced
about whether primary care could continue to cope with-
out additional support [2]. Currently, about 70 to 80% of
people in the United Kingdom (UK) with T2DM are
managed entirely in primary care. There is long-standing
and continued evidence of deficiencies in provision of
care and significant variations between general practices
[3,4]. More recently, differences in quality of care and
outcomes have been reported depending on the model of
care adopted or staff levels of experience [5,6]. Practices
in areas of high deprivation and mix of ethnicity are less
likely to achieve adequate levels of control [7-9].
There is evidence from randomized controlled trials
that intensive management of T2DM can reduce com-
plications such as retinopathy, nephropathy and neur-
opathy, as well as reducing the risk of cardiovascular
disease [10]. Benefits are seen from improved glycemic
control, lower blood pressure and better management
of lipids [11-13]. Patients with improved glycemic con-
trol also consistently report better functional status and
wellbeing [14-16].
It is less clear how benefits seen in individual ex-
planatory trials might be realized in a new integrated
service model. A Cochrane review found evidence
that structured recall, patient education, and support
from specialist nurses can lead to better outcomes
[17], and a trial in Danish general practice found that
intensive patient-focused management led to signifi-
cant risk reduction [18]. Economic modeling also sug-
gests that intensive control of risk factors is likely to
be cost-effective in the UK [19]. Although the evi-
dence indicates that access to multidisciplinary,
community-based services can support general prac-
tices in achieving good clinical control of their dia-
betic patients, and possibly improve patient outcomes,
it is unclear what the optimum combination or model
might be for service provision.One method suggested is introduction of intermediate
care clinics for diabetes (ICCD). The intermediate care
model aims to deliver high-quality care nearer to the pa-
tient through multidisciplinary, locality-based teams, with
the added opportunity for developing professional expert-
ise in the community and hopefully reducing care costs. A
common approach is for medical care to be provided by
general practitioners (GPs) with a special interest (GPwSI)
in diabetes [20] working with community-based specialist
teams. ICCDs began to be introduced in the UK in 2004.
A descriptive evaluation found that intermediate care
clinics were popular with patients and practitioners and
appeared to reduce outpatient attendances by 25% [21].
However, inherent in the ICCD model is a trade-off be-
tween the higher levels of technical expertise available in
the clinic versus a reduction in the continuity of care as
previously provided solely by the GP practice. Continuity
of care has been shown to be related to glycemic control
[22]. The costs of the two models will also differ, and the
cost-effectiveness of ICCD introduction remains unclear.
To date, there have been a number of other ICCD
services established in the UK, although the staffing
and organization of these varies and none has been
introduced under trial conditions with an integral
economic evaluation. One service, set up in Cardiff,
Wales, has reported some consideration of costs and
benefits, although no data on the impact of this
ICCD model on costs and patient outcomes are avail-
able [23]. Other initiatives include Somerset Commu-
nity Health [24]; an ICCD service established in
Southampton [25]; and an ICCD team set up in Lam-
beth, London [26]. The latter has reported that the
service is marginally cost saving [27]. No other eva-
luations have been published.
The present study protocol describes a cluster rando-
mized controlled trial of an ICCD intervention set up in
three Primary Care Trusts (PCTs) to improve outcomes
for primary care patients with T2DM. In accordance
with the Medical Research Council’s framework for de-
velopment and evaluation of complex interventions the
trial intervention built on published and ongoing forma-
tive research [28,29].
Practices recruited to the study are randomized to
either usual care or intervention arm, with the latter
having access to the new ICCD clinics. In participating
practices, patients with T2DM are invited to take part
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baseline assessment by a study nurse. This includes
measurement of HbA1c, body mass index (BMI), waist
circumference, blood pressure, urine and lipids. Partici-
pating patients are asked to attend a follow-up assess-
ment 18 months after their baseline assessments, when
the same measurements are repeated. Questionnaires
about quality of life, satisfaction with current services,
continuity of care and health service use and personal
costs are completed at baseline and follow-up. An inte-
gral economic evaluation measures costs in both
groups, with a comparative assessment of marginal costs
and outcomes. To deal with possible selection bias, risk
factor control of all patients with T2DM in intervention
and control practices will be compared using anon-
ymised GP data. Additionally, a qualitative study is ex-
ploring the views of patients, health professionals and
other stakeholders using semi-structured interviews.
The overall aim is to conduct a randomized controlled
trial to evaluate the effectiveness and cost-effectiveness
of community-based intermediate care clinics in the
management of T2DM. Specific objectives are to:
1. Compare the following in patients with T2DM
registered with practices that have access to ICCD
with those that have access only to usual care: control of cardiovascular risk factors including
glycemic, blood pressure and lipid control, and
cardiovascular risk assessed by UKPDS risk engine;
 quality of life;
 satisfaction with services and continuity of care;
 referral patterns and non attendance rates;
 annual cost per patient with diabetes.
2. Estimate the difference in the cost of the resources
used by patients in each arm of the trial, and the
cost-effectiveness of the ICCD intervention.Number of practices in participation PCTs
Number practices recruited to study
Practice randomisation by 
size and PCT
Intervention (ICCD)
24 practices
Patients with T2DM
(n=12,340) 5,606
Patients consenting
(n=1,997) 1,057
Final assessment 
(18 month follow-up) 644
Figure 1 Study design and flow chart.3. Explore the views and experiences of patients, health
professionals and other stakeholders.
Methods/Design
Study design
This pragmatic trial is a two-arm parallel group cluster
randomized controlled trial, with randomization at the
GP practice level. Practices recruited to the study are
randomized to the intervention or control arm. Practices
in the intervention arm have access to ICCD. Those ran-
domized to usual care are issued with local guidelines
and continue to manage their patients, including hospital
referrals, in the usual way. All patients with T2DM in
participating practices are eligible for inclusion in the
study; up to 100 patients per practice will be recruited.
Patients consenting to take part are asked to attend a
baseline assessment and then a follow-up assessment at
the end of the 18-month intervention period. The trial
will assess differences in the percentage of patients
achieving adequate control of HbA1c, cholesterol and
blood pressure (combined) among patients who have ac-
cess to ICCD in comparison with patients receiving
standard care. The study is also designed to examine the
effect of access to an ICCD on process measures such as
contacts with hospital services and general practice. Add-
itionally, semi-structured interviews are being under-
taken in the intervention arm to explore the views and
experiences of patients, health professionals and other
stakeholders. The study design is shown in Figure 1.
The study protocol was approved by Trent Multi-centre
Research Ethics Committee (REC Ref 06/MRE04/41), with
amendment to sample size accepted in August 2006.
Sample size
We initially planned to recruit a total of 5,000 patients
from 51 practices (25 in one trial arm, and 26 in the
other), with approximately 100 patients being recruited98
49
Control
25 practices
6734
940
636
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expected the final number of patients in each practice to
be 72, or approximately 3,700 patients in total.
Estimates for the percentage of patients achieving con-
trol in the usual care group are taken from a UK survey
[4]. We used HbA1c for our primary sample size calcula-
tion as this is the outcome variable for which there is
the most robust information on intra-class correlation
(ICC). To detect a difference of percentage well-
controlled (HbA1c <7.5%) from 50% in the control group
to 60% in the intervention group (α= 0.05, Power = 0.8
not allowing for clustering, requires a sample size of 408
subjects in each arm. Using an Intra-class correlation
(ICC) of 0.047, and with 72 patients in each cluster, the
necessary sample size in each arm is 1770, representing
a total of 3,540 patients for both arms. This number is
also adequate to detect a 10% difference in cholesterol
control (from 60% to 70%) and blood pressure control
(from 60% to 70%). Estimates of ICC for blood pressure
and cholesterol are taken from the UK Asian Diabetes
Study (UKADS), a study of care provision for people of
South Asian ethnicity with diabetes [30]. Assuming the
ICC for our combined primary outcome (adequate con-
trol of HbA1C, blood pressure and cholesterol) is 0.05
and achievement is at 20% in the control arm and 30%
in the intervention arm, we would need a total of 2,848
patients.
During the recruitment phase, it became clear that we
would fall short of the intended 5,000 patients, and of
the expected 72 patients per practice. A revised sample
size estimate of 40 patients in each practice after follow
up (approximately 2,000 patients in total) was proposed
and accepted by the ethics panel. Using the same ICC
values as previously, and considering the primary out-
come, the necessary sample size in each arm is 1,022, for
a total of 2,044 (note that this is the necessary sample
size for patients retained at follow-up; the sample size
for initial recruitment must therefore be larger, or
according to our estimates, at least 2,555). This value is
approximately sufficient to give power of 80% to detect a
10% difference for both the combined primary outcome
and control of blood pressure. We can restore the power
to that of the original protocol, before the changes to
sample size were made, by considering the detection of a
12% difference for these measures. For control of HbA1c
and cholesterol the power is slightly less than 80%.
Setting/ participants
The study is taking place in general practices in three
PCTs in a geographically and socially diverse sub-region
of England. Providing good quality care for people with
diabetes is a particular challenge for the health services
in these areas given the prevalence of the condition, par-
ticularly in minority ethnic groups.Practices
All GP practices in the three participating PCTs were
first invited to express an interest in participating in the
trial. Experience from a similar trial of community cardi-
ology clinics in Leicester suggested that over 80% of
practices would agree, as it gives them an even chance
of accessing an additional service for their patients [31].
The aim was to recruit 51 practices in total (52% of all
eligible practices).
Patients
To be eligible for inclusion in the trial, potential partici-
pants must be patients in a participating practice, as well as:
a) be adults aged 18 years or older;
b) have T2DM;
c) not have severe cognitive impairment which would
preclude active engagement in the trial;
d) not be pregnant at recruitment
e) not have a severe mental illness (for example, anxiety
or depression, which would preclude active
engagement in the trial);
f ) not be receiving terminal care;
g) receive a letter of invitation to the study from their
practice;
h) express a wish to participate and provide written
consent.
Study intervention
Following development work, community-based ICCDs
were established in the participating PCTs. These are
designed to work closely with hospital-based specialist
teams and community services, including podiatry and
dietetics, in order to support primary care, particularly
smaller practices that have the most difficulty achieving
good control for their patients. Each ICCD consists of a
multidisciplinary team, led by a specialist nurse, with
emphasis placed on education and self-management.
Medical care is provided by a diabetes specialist or a GP
with a special interest (GPwSI) in diabetes and, in prac-
tices with access to the service, patients with T2DM are
no longer referred to hospital directly. Guidelines for re-
ferral to the ICCDs are common across all sites, and in-
clude people with poorly controlled T2DM and those
with poorly controlled cardiovascular risk factors.
Patients are managed by the ICCD team until control of
risk factors is achieved and then participants are referred
back to primary care. The team members work to local
guidelines, adapted from national evidence-based guide-
lines [32].
At both sites the planned capacity is for 20% of
patients with T2DM to attend the ICCD per annum, as-
suming that on average patients will be seen four times
in the ICCD before returning to primary care.
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The launch of the trial was phased across participating
PCTs. Following baseline assessments, practices were
randomized and the clinic launched. Eighteen months
later follow-up assessments were begun, ensuring that
all patients in the intervention arm had 18 months ex-
posure to the ICCD.
Primary clinical outcome measure
The primary outcome measure is the proportion of parti-
cipants reaching all three of the following targets - HbA1c
(≤7.0%), blood pressure (<140/80), and total cholesterol
(<4 mmol/l), as stated in National Institute of Health and
Clinical Excellence (NICE) guidelines for patients with
T2DM [33].
If the primary outcome measure is achieved this would
represent a significant health gain. The trial aims to detect
a 10% difference in the level of control in the intervention
arm practices (whether or not patients attend ICCD) com-
pared with practices in the usual care group. Audit data
suggest that, in participating practices, about 15% of
patients will have this level of control at baseline. We ex-
pect an increase of no more than 5% in the control arm.
Secondary outcome measures
Secondary outcomes are the proportion of participants
reaching targets for individual risk factors (blood pres-
sure, HbA1c or cholesterol) and 10-year risks for CHD
and stroke assessed by the UKPDS risk engine [34]. In
order to collect sufficient data items to use the UKPDS
risk engine, the Practice Record Extraction list was
amended to include:
 duration of diabetes (years)
 age at diagnosis (years)
 smoking status at time of diabetes diagnosis
Other biomedical markers include BMI and waist cir-
cumference, as well as use of medication, reported
smoking, costs, quality of life, emotional adjustment, pa-
tient satisfaction and views on continuity.
Additional outcome measures
The study also proposes obtaining routinely collected
data from all patients with T2DM in participating prac-
tices. The following data will be extracted by practice
staff and all identifiers will be removed before the data is
given to research staff:
1. date of diagnosis of T2DM
2. latest reading with date entered for the following
(excluding data entered after the date ICCDs are
launched): blood pressure, total cholesterol, HbA1c,
and smoking status.3. socio-demographic data including age (years), sex,
and ethnicity index of multiple deprivation score
(IMD, derived from patient’s postcode, using IMD
2007).
4. practice code.
Permission to obtain the data will be sought from each
participating practice. The data will be extracted by
members of staff from the practice using the Morbidity
Information Query and Export Syntax (MIQUEST) or
similar audit tool and will be transferred into an excel
file, which will not contain any personally identifiable
data. Instructions on how to complete the audit will be
supplied by the study team. These data will be collected
from the practice by the trial coordinator and will be
stored and saved according to Data Protection Act
regulations.Patient assessments
Patient assessments are being conducted by a trained re-
searcher on practice premises, using standard operating
procedures. Baseline assessments are necessary as GP
data are non-standardized and will be up to a year old.
It is not feasible for researchers to be blinded to alloca-
tion, but outcome measures are all objective; an auto-
mated sphygmomanometer is used and results of
laboratory blood analyses are extracted from GP or local
hospital systems. As assessments take place throughout
the day, obtaining fasting blood samples is not feasible.
Patient biomedical markers consist of blood pressure,
blood lipids, HbA1c, BMI, waist circumference, protein-
uria, miroalbumiuria and self-reported smoking. In
addition to the European Quality of Life-5 Dimensions
(EQ-5D) standardized measure of health status devel-
oped by the EuroQol Group [35], health status is also
being assessed using the short version of World Health
Organization’s Quality of Life. We are also assessing sat-
isfaction with services using the Diabetes Treatment Sat-
isfaction Questionnaire (DTSQ) [36] emotional
functioning using the Problem Areas in Diabetes (PAID)
scale [37]) and continuity of care using a Continuity of
Care Questionnaire [38,39]. All these questionnaires are
used at both assessments. Additionally, the baseline as-
sessment includes demographic data and prescribed
medication. The GP records of patients are also flagged
electronically to encourage reporting of death or change
of GP.
GPs will be informed of results contributing to na-
tional Quality and Outcomes Framework (QOF) indica-
tors which reward GP practices for the provision of
‘quality care’. These include blood pressure, weight/BMI,
HbA1c, lipids, microalbuminuria and smoking status.
This is done because it is possible that patients attending
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routine clinical assessments.
Economic outcome measures
Data on NHS resource use and personal costs to
patients are being collected using standard measures for
economic analysis [40]. Direct NHS costs include the
number of referrals to and attendances at ICCD in the
intervention arm and to hospital in the control arm. We
are also recording the number of GP, practice nurse, op-
tometrist, podiatrist and dietician consultations, and
total hospital attendances, which include both inpatient
and outpatient visits. Data are also being collected on
prescribed medication and tests linked to diabetes, in-
cluding diabetic retinopathy tests. For patients who are
referred to ICCD, we note the number of contacts with
professionals, as well as any group or educational inter-
vention. Direct personal cost data include personal ex-
penditure such as travel costs and indirect costs such as
days off sick from work or reduced hours of employ-
ment are being collected. These data are obtained at the
time of the follow-up assessment.
Impact on health utility will be assessed using the EQ-
5D questionnaire [35,41]. Comparing this with costs
(directly and indirectly related to patient management)
will enable incremental cost-effectiveness of the inter-
vention to be estimated.
Qualitative study
Qualitative data focusing on the views and experiences of
patients, health professionals and other stakeholders are
being collected. Semi-structured exploratory interviews
will be undertaken with a sample of approximately 20
patients who have experienced the intervention. This is
planned to be a purposive sample, based on responses to
the quantitative questionnaires administered at the end
of the study. For patients requiring a caregiver, both the
patient and caregiver will be interviewed. Where a pa-
tient does not speak English, a translator is engaged. A
prompt guide was developed through discussion follow-
ing a literature review and modified after initial piloting.
The interviews focus on the patients’ experiences com-
pared to their previous usual care. Participants are free to
choose the day, time and venue for the interview. Wher-
ever possible, interviews will be undertaken face-to-face.
If necessary, the interview is undertaken by telephone.
The choice of face-to-face or telephone follow-up will be
decided by the researcher in consultation with the
patient, and is dependent on the patient’s own preference.
In addition, semi-structured interviews with health
professionals and other stakeholders are being used to
explore views in ICCD and experiences of the service.
As with the patient interviews, a prompt guide was
developed and modified after initial piloting.Patients whose preferred language is not English
We are using translated versions of questionnaires if
available (for example the EQ-5D). Questionnaires are
only completed by people who are fluent in the language
of the questionnaire. In circumstances where a patient’s
spoken understanding of a language is better than their
understanding of written material, we will ask someone
to read the questionnaire to them without attempting any
translation. All trial literature (that is, consent forms and
Patient Information Sheets) is translated. The consent
form and patient information sheet have been translated
into Bengali, Punjabi, Gujarati and Urdu languages.
Trial procedures
Practice recruitment
The study team first contacted all practices in the rele-
vant PCTs. Practices were sent an invitation letter and
short information sheet via the post, and invited to ex-
press an interest in participating in the trial. For prac-
tices that express an interest, data on current levels of
control of patients with T2DM were examined (%
patients with HbA1c <7.5, BP145/85 mmHg or less and
cholesterol 5 mmol/l or less). These are routinely col-
lected as part of the GP contract [42] and those practices
with the highest proportions of poorly controlled
patients were invited to join the study.
Practices are recruited on the understanding that they
will have access to results on weight, blood pressure,
lipids, HbA1c and microalbuminuria from the assess-
ments of patients belonging to their practice. Blood and
urine samples are sent to the laboratory for analysis and
results sent to practices in the usual way. Research staff
record the patient’s blood pressure and weight in the
patient’s electronic health records, subject to prior per-
mission from the practice.
Practice randomization
Practices recruited to the study were randomized to an
intervention or control arm, stratified by practice size
and PCT to achieve similar numbers in each arm of the
trial. Practices in the intervention arm have access to
ICCD service. The study design anticipated that up to
30% of patients in any practice might be eligible for re-
ferral to ICCD. Those practices randomized to usual
care are issued with local guidelines and continue to
manage their patients (including hospital referrals) in
the usual way.
Randomization, stratified by area and GP practice size,
was undertaken independently of the trial team by War-
wick Clinical Trials Unit.
Patient recruitment
All patients with poorly controlled T2DM were
approached by a letter from their GP enclosing the study
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received by the research team, patients were written to
or telephoned, as appropriate, to explain the aims of the
study and arrange an assessment appointment, at which
time written consent was obtained by a researcher. An
appointment confirmation letter and further copy of the
patient information sheet was sent to the patient by post.
The aim was to recruit a total of 2,000 patients from 51
practices, with each recruiting approximately 40 patients
with poorly controlled T2DM who would be suitable for
referral for ICCD support. In a similar study in Denmark
94% consented [18], but assuming a lower consent rate,
as seen in UKADS [30] we expect an average sized par-
ticipating practice with 150 patients with diabetes to re-
cruit 40 to 100 patients. Those not responding to
requests for follow-up attendance were reminded using
letters, telephone, email and texting.
To enhance the participation rate, GPs and practice
nurses at participating practices have been asked to
introduce any eligible patients to the study opportunis-
tically as they consult. The research team also offered
evening assessment appointments centrally since even-
ing appointments are not possible at general practices
due to earlier closing times. Patient confidentiality is
assured at non-practice venues, using a locked secure
Case Report Form (CRF) box stored in a secure location.
Access to the CRF box is restricted to the trial coordin-
ator and research assessors. Laboratory tests are pre-
pared, sent and received in line with usual hospital
protocol. To protect patient confidentiality, the patient’s
medical history and medication summary notes are
extracted from the practice database by a member of the
research team, after informed consent has been obtained
from the patient.
Analysis
Statistical analysis
Intention-to-treat (ITT) comparisons of the two groups
will be conducted, with the primary dependent variable
being the proportion of patients achieving all three clin-
ical targets at 18 months. The main analysis will be
based on all patients recruited to the study. As some
drop-outs and losses are inevitable, sensitivity style ana-
lyses are planned. Missing data imputation will use ‘last
observation carried forward’ (LOCF). Secondary analyses
will exclude all observations with missing values. Ana-
lyses will use a mixed effects logistic regression model,
and will adjust for baseline characteristics at both prac-
tice and individual level. The former may include prac-
tice size and deprivation index, and the latter age,
gender, BMI, ethnicity, employment status, educational
level and length of time since diagnosis. Characteristics
will be included using a forward selection model-
building strategy, with only variables significant at the10% level selected. Odds ratios (OR) will be estimated
with 95% confidence intervals, adjusting for potential
confounding variables and allowing for the effect of the
cluster randomization [43].
Further analysis will examine secondary outcomes
(achievement of individual targets for blood pressure,
HbA1c and lipids), again adjusting for confounders and
allowing for the cluster randomization. In addition,
UKPDS 10-year risk scores for CHD and stroke will be
analyzed using a linear mixed model.
Tertiary analysis of questionnaire responses will con-
sider longitudinal continuity, flexible continuity, rela-
tional continuity and term and boundary continuity
following the NCCSDO methodology on ‘continuity of
care in type 2 diabetes’ [44]. We will also compare the
levels of ICCD use by the intervention practices, and the
drop-out rates for all practices.
Finally, all analyses will be re-run with added data
from MIQUEST covering all diabetes patients in a prac-
tice whether recruited to the trial or not [45]. This will
lessen the number of variables available, but otherwise
all analyses for primary and secondary endpoints will be
repeated.
Economic evaluation
Economic evaluation methods will, as far as possible, ad-
here to the recommendations of the NICE Reference
Case [46]. The economic evaluation will consist of a
within-trial analysis and economic modeling. Within
trial analysis will compare direct costs and 18-month
outcomes of patients randomized to intervention versus
control. The primary perspective adopted will be that of
direct NHS and patient costs. A costing study will rec-
ord intervention costs (to include staff time, capital,
overheads and consumables), other NHS resource use
(for example, GP visits, hospital visits, and admissions)
and selected patient expenditure. Unit costs for health
care resources will be derived from local and national
sources and performed in line with best practice [47].
Costs will be standardized to current prices where pos-
sible. Because of the short follow-up period, we will not
discount costs or benefits.
Comparison will be made between baseline and
follow-up to estimate incremental cost-effectiveness
ratios (ICERs) comparing the intervention with the con-
trol group in terms of the primary outcome measure
(patients achieving all three clinical targets) and costs
[40]. Quality of life (EQ-5D) over the study period will
be used to generate quality-adjusted life-years (QALYs)
[48]. Outputs will be presented as ICERs, cost-
effectiveness acceptability curves and expected net bene-
fit. Sensitivity analyses will consider key cost drivers and
factors that might affect the outcomes measured in
order to explore uncertainty in the conclusions drawn.
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All interviews are being audio-recorded with the par-
ticipants’ consent and later transcribed verbatim. Par-
ticipants are allocated a study number to ensure
confidentiality. Interviews will be analyzed using Frame-
work analysis [49], a systematic and comprehensive
method of classifying and interpreting qualitative data
particularly concerned with generating policy- and
practice-orientated findings [50]. The process will begin
with familiarization with the data and identification of
both broad and sub-themes, followed by continual re-
assessment and reinterpretation of these emerging
themes and the original transcripts. A ‘framework’ for
each theme will be created in which data will be charted
against individual participants. This process will retain
the original context and quotes, and facilitate explor-
ation of the range of comments made under each theme
and the relationships between themes.
Discussion
The present study will provide a robust estimate of the
effects of introduction of intermediate care clinics for
diabetes to support the care of patients in UK primary
care, and the costs associated with any improvements in
outcomes produced. The ICCD model aims to deliver
high quality care through a multidisciplinary, locality-
based team, with the added opportunity for developing
professional expertise in the community. The results of
this trial will be of direct policy relevance to the devel-
opment of diabetes services in the UK, and will provide
clinical commissioning groups with evidence to inform
decisions on commissioning services to improve control
in T2DM. Diabetes and service reconfiguration are both
national research priorities but there is an urgent need
to base policy on evidence. Modeling suggests the
ICCDs will be cost-effective in reducing complications
and consequent hospital admissions, as well as produ-
cing societal benefits such as reduced incapacity to work.
If results from this short-term evaluation are positive
they will provide an initial evidence base for adoption
and for longer-term evaluations to assess the benefits
predicted from modeling. The qualitative study will help
identify factors influencing service uptake and, if the trial
finds no significant effect, why efficacy was not demon-
strated. Forty-nine practices have been randomized and
1,997 patients recruited to the trial. Follow up finished
in October 2011 and the results will be available in late
2012. It is not possible at present to comment on the ef-
fectiveness or cost-effectiveness of an ICCD service.
Trial status
At the time of submission, patients were being recruited
to the qualitative study, and both follow-up assessments
and MIQUEST searches were ongoing.Abbreviations
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